Primenenie preparata Ksenikal dlya lecheniya ozhireniya u podrostkov

1. Ожирение: этиология, патогенез, клинические аспекты. /Под ред. И.И.Дедова, Г.А.Мельниченко. - М.: Медицинское информационное агентство, 2004.

2. Старкова Н.Т., Малыгина (Бирюкова) Е.В., Мураховская Е.В. и др. Применение ксеникала при гипоталамическом ожирении у лиц молодого возраста.// Пробл. эндокринологии 2002; 48 (3): 27-30.

3. Clemens, TL, Adams, JS, Henderson, SL, Holick, MF. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet 1982; 1: 74-76.

4. Davidson M.H., Hauptman J., Di Girolamo M. et al. Weight control and risk factors reduction in obese subjects treated for 2 years with orlistat. A randomized controlled trial. JAMA 1999; 281: 235-242.

5. de Ferranti S.D., Gauvreau K., Ludwig D.S., et al. Prevalence of the metabolic syn- drome in american adolescents. Findings from the Third National Health and Nutrition Examination Survey. Circulation 2004;110: 2494-2497.

6. Diamond F.B. Newer aspects of the pathophysiology, evaluation and management of obesity in childhood. Curr Opin Pediatr 1998; 10: 422-427.

7. Finer N., James W.P., Kopelman P.G. et al. One-year treatment of obesity: a ran- domized, double-blind, placebo-controlled, multicentre study of orlistat, a gastroin- testinal lipase inhibitor. Int J Obes Relat Metab Disord 2000; 24: 306-313.

8. Matsuoka LY, Wortsman J, Chen TC et al. (1995) Compensation for the interracial variance in the cutaneous synthesis of vitamin D. J Lab Clin Med 1995; 126: 452-457.

9. Matsuoka LY, Wortsman J, Haddad et al. (1991) Racial pigmentation and the cuta- neous synthesis of vitamin D. Arch Dermatol 1991; 127: 536-538.

10. McDuffie J.R., Calis K.A., Booth S.L. et al. Effect of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 2002; 22 (7): 814-822.

11. McDuffie J.R., Calis K.A., Uwaifo G.I. et al. Efficacy of orlistat as an adjunct to behavioral treatment in overweight African-American and Caucasian adolescents with obesity-related co-morbid conditions. J Pediatr Endocrinol Metabol 2004; 17: 307-319.

12. McDuffie J.R., Calis K.A., Uwaifo G.I. et al. Three-mounth tolerability of orlistat in adolescents with obesity related comorbid conditions. Obes Res 2002; 10 (7): 642-650.

13. Norgren S., Danielsson P., Jurold R. et al. Orlistat treatment in obese prepuber- tal children: a pilot study. Acta Paediatr. 2003; 92 (6): 666-70.

14. Ozkan B., Bereket A., Turan S. and Keskin S. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr 2004; 163 (12): 738 - 741.

15. Srinivasan S.R., Myers L., and Berenson G.S. Predictability of childhood adiposi- ty and insulin for developing insulin resistance syndrome (syndrome X) in young adulthood. The Bogalusa Heart Study. Diabetes 2002; 51:204-209.

16. Styne D.M. Childhood and adolescent obesity. Prevalence and significance. Pediatr Clin North Am 2001; 48 (4): 823 - 854.

17. Wang Y., Monteiro C. and Popkin B.M. Trends of obesity and underweight in older children and adolescents in the United States, Brazil, China, and Russia. Am J Clin Nutr 2002; vol. 75 (6): 971-977.

18. Zhi J., Moore R., Kanitra L. The effect of short-term (21-day) orlistat treatment on the physiological balance of six selected macrominerals and microminerals in obese adolescents. J Amer Coll Nutr 2003; 22 (5): 357-362.

19. Данные компании Ф. Хоффманн-ЛяРош.